Movement Alert｜Gilead Sciences Overnight Rise 3.27%, Focus Turns to Quarterly Results and a Constructive Analyst Backdrop

Market Focus10-29 08:53

On October 29, Gilead Sciences rose 3.27% Overnight, trading at $164.4/share, with turnover of $85.9 thousand. The most direct backdrop in public information is heightened market attention ahead of the company’s quarterly results due later that day, with consensus calling for revenue of $7.797 billion, up 4.71% year over year, and adjusted EPS of $2.20, up 3.04%.

Recent developments have reinforced that constructive setup. Multiple firms lifted price targets earlier in October, including moves to $170, $168, $184 and $142, while the broader analyst average remained Overweight. Investors have also been watching key HIV products and oncology asset Trodelvy, alongside expense discipline, as potential swing factors for the quarter.

Outside earnings, Gilead also announced a $1.28 billion cash deal to acquire PepStar Therapeutics’ oral inflammation drug program, including Phase 1 asset HCXT-2001, expanding its inflammatory bowel disease pipeline. The company said the transaction is expected to close in the fourth quarter and will reduce fourth-quarter GAAP and non-GAAP earnings per share.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1185327475?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-29 08:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1185327475","market":"us","top_or_hot":-1,"title":"Movement Alert｜Gilead Sciences Overnight Rise 3.27%, Focus Turns to Quarterly Results and a Constructive Analyst Backdrop","media":"Market Focus","content":"<p><p>On October 29, Gilead Sciences rose 3.27% Overnight, trading at $164.4/share, with turnover of $85.9 thousand. The most direct backdrop in public information is heightened market attention ahead of the company’s quarterly results due later that day, with consensus calling for revenue of $7.797 billion, up 4.71% year over year, and adjusted EPS of $2.20, up 3.04%.</p><p>Recent developments have reinforced that constructive setup. Multiple firms lifted price targets earlier in October, including moves to $170, $168, $184 and $142, while the broader analyst average remained Overweight. Investors have also been watching key HIV products and oncology asset Trodelvy, alongside expense discipline, as potential swing factors for the quarter.</p><p>Outside earnings, Gilead also announced a $1.28 billion cash deal to acquire PepStar Therapeutics’ oral inflammation drug program, including Phase 1 asset HCXT-2001, expanding its inflammatory bowel disease pipeline. The company said the transaction is expected to close in the fourth quarter and will reduce fourth-quarter GAAP and non-GAAP earnings per share.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Gilead Sciences Overnight Rise 3.27%, Focus Turns to Quarterly Results and a Constructive Analyst Backdrop</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Gilead Sciences Overnight Rise 3.27%, Focus Turns to Quarterly Results and a Constructive Analyst Backdrop\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-10-29 08:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On October 29, Gilead Sciences rose 3.27% Overnight, trading at $164.4/share, with turnover of $85.9 thousand. The most direct backdrop in public information is heightened market attention ahead of the company’s quarterly results due later that day, with consensus calling for revenue of $7.797 billion, up 4.71% year over year, and adjusted EPS of $2.20, up 3.04%.</p><p>Recent developments have reinforced that constructive setup. Multiple firms lifted price targets earlier in October, including moves to $170, $168, $184 and $142, while the broader analyst average remained Overweight. Investors have also been watching key HIV products and oncology asset Trodelvy, alongside expense discipline, as potential swing factors for the quarter.</p><p>Outside earnings, Gilead also announced a $1.28 billion cash deal to acquire PepStar Therapeutics’ oral inflammation drug program, including Phase 1 asset HCXT-2001, expanding its inflammatory bowel disease pipeline. The company said the transaction is expected to close in the fourth quarter and will reduce fourth-quarter GAAP and non-GAAP earnings per share.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GILD","symbol_name":"吉利德科学","start_time":0,"source_url":"","article_id":"1185327475","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1185327475","pubTimestamp":1793235197,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On October 29, Gilead Sciences rose 3.27% Overnight, trading at $164.4/share, with turnover of $85.9 thousand. The most direct backdrop in public information is heightened market attention ahead of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GILD":"吉利德科学"},"translate_title":"走势警报|吉利德科学隔夜上涨3.27%，焦点转向季度业绩和建设性分析师背景","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GILD":1},"content_text":"On October 29, Gilead Sciences rose 3.27% Overnight, trading at $164.4/share, with turnover of $85.9 thousand. The most direct backdrop in public information is heightened market attention ahead of the company’s quarterly results due later that day, with consensus calling for revenue of $7.797 billion, up 4.71% year over year, and adjusted EPS of $2.20, up 3.04%.Recent developments have reinforced that constructive setup. Multiple firms lifted price targets earlier in October, including moves to $170, $168, $184 and $142, while the broader analyst average remained Overweight. Investors have also been watching key HIV products and oncology asset Trodelvy, alongside expense discipline, as potential swing factors for the quarter.Outside earnings, Gilead also announced a $1.28 billion cash deal to acquire PepStar Therapeutics’ oral inflammation drug program, including Phase 1 asset HCXT-2001, expanding its inflammatory bowel disease pipeline. The company said the transaction is expected to close in the fourth quarter and will reduce fourth-quarter GAAP and non-GAAP earnings per share.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1185327475","isCrawlerRequest":true}